Key Takeaways:
BridgeBio Pharma (NASDAQ: BBIO) executives projected de-risked peak-year sales of over $8 billion across four key products, reinforcing confidence in its commercial drug Attruby and a trio of near-term pipeline candidates at a recent BofA healthcare conference.
"We see more than $8 billion in de-risked peak-year sales potential within reach across Attruby and the next three products," Tom Trimarchi, BridgeBio’s chief financial officer and president, said, highlighting the company's growth trajectory from its founding over 10 years ago.
The company's main commercial driver, Attruby, generated $180.6 million in first-quarter U.S. revenue and is on track to exceed blockbuster status this year. Management reiterated a peak U.S. sales forecast of about $4 billion for the ATTR-CM treatment. The guidance is supported by a market opportunity estimated between $15 billion and $20 billion and a growing market share of over 25% among new patients.
The forecast hinges on the successful launch of three additional drugs and continued market penetration against competitors. The company recently submitted a New Drug Application for encaleret in ADH1, with a potential U.S. launch in early 2027, which could be the first approved therapy for the condition.
BridgeBio detailed its late-stage pipeline, which includes three assets with upcoming launches. The products are BBP-418 for limb-girdle muscular dystrophy Type 2I, encaleret for ADH1, and infigratinib for achondroplasia.
The company has submitted its NDA for encaleret following a successful Phase 3 trial where 76% of participants met the primary endpoint, compared to just 4% on conventional therapy. BridgeBio estimates a potential billion-dollar market for encaleret in ADH1 alone and plans to initiate a Phase 3 study for the drug in a broader chronic hypoparathyroidism indication in the summer of 2026.
For BBP-418, BridgeBio estimates a patient population of about 7,000 in the U.S. and Europe. Meanwhile, executives highlighted infigratinib's potential as a convenient oral option for achondroplasia, a condition that may otherwise require daily or weekly injections.
Executives expressed confidence in Attruby's position as a first-line treatment, citing physician preference for oral stabilizers due to their efficacy, safety, and convenience over injections. Despite competition from established products like Pfizer's Vyndamax, BridgeBio has captured over a quarter of the market for patients starting a new treatment. The company is leveraging a 30-day free drug program to encourage adoption.
This guidance provides investors with a clearer picture of BridgeBio's multi-product commercial strategy. The successful execution of these three upcoming launches, alongside continued growth for Attruby, will be critical for the company to achieve its ambitious $8 billion sales target.
This article is for informational purposes only and does not constitute investment advice.
